Liraglutide Effects on Memory in Healthy Subjects

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study examines the hypothesis, that subcutaneous administration of liraglutide, an analogue of the incretin glucagon-like peptide 1, over 5 weeks improves memory functions in healthy humans.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Luebeck
• Collaborator: Novo Nordisk A/S
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Male sex

• Age 18-35 years

• Body mass index between 19 and 25 kg/m2

• Non-smoker

Exclusion Criteria:

• Receipt of any drug within 4 weeks prior to this trial

• Any known acute or chronic disease of the brain, heart, lung, kidney,liver, pancreas or gastrointestinal tract, any metabolic, endocrine or psychiatric disease.

• Brady- and Tachycardia, i.e. heart rate < 50 and > 90 beats per minute.

• Hypertension (systolic blood pressure > 150 mmHg, diastolic blood pressure > 90 mmHg).

• Hyperlipidemia (cholesterol, LDL, triglyceride > two times the upper reference limit based on analysis from the central laboratory)

• Impaired hepatic function measured as alanine aminotransferase (ALAT) > two times the upper reference limit based on analysis from the central laboratory

• Impaired renal function measured as creatinine > 120 µmol/l based on analysis from the central laboratory

• Family history of diabetes

• History of any eating disorder

• Known or suspected allergy to trial products

• History of drug or alcohol abuse within the last five years prior to screening